1. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H et al. (2006) Borderline resectable pancreatic cancer: defini- tions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035 – 1046.
2. Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS et al. (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 270:248 –260.
3. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP et al. (2013) Borderline resectable pancreatic cancer: need for standardiza- tion and methods for optimal clinical trial design. Ann Surg Oncol 20: 2787 –2795.
4. Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kinoshita T et al. (2011) Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci 18:567 – 574.
5. Yamada S, Fujii T, Takami H, Hayashi M, Iwata N, Kanda M et al. (2017) Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Surgery 162: 784 – 791.
6. Murakami Y, Satoi S, Sho M, Motoi F, Matsumoto I, Kawai M et al. (2015) National comprehensive cancer Network resectability status for pancreatic carcinoma predicts overall survival. World J Surg 39: 2306 –2314.
7. Japan Pancreas Sosaety. (2017) Classification of pancreatic carcinoma, 4th English ed Tokyo: Kanehara.
8. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB et al. (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833 –848.
9. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA et al. (2014) Borderline resectable pancreatic cancer: a consensus statement by the international study group of pancreatic surgery (ISGPS). Surgery 155:977– 988.
10. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernandez-Del Castillo C, Hackert T et al. (2018) International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18:2 –11.
11. NCCN clinical practice guidelines in oncology (NCCN Guide- lines®).(2017). https://www.nccn.org/professionals/physician_gls/pdf/ pancreatic.pdf. [Accessed 6 April 2018].
12. Nakao A, Takagi H. (1993) Isolated pancreatectomy for pancreatic head carcinoma using catheter bypass of the portal vein. Hepatogas- troenterology 40:426– 429.
13. Nakao A, Takeda S, Inoue S, Nomoto S, Kanazumi N, Sugimoto H et al. (2006) Indications and techniques of extended resection for pancreatic cancer. World J Surg 30:976 – 984.
14. Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, Gonzalez P, Gonzalez B, Mancha A et al. (2005) CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 20: 38–45. Kanda Y. (2013) Investigation of the freely available easy-to-use soft- ware ’EZR’ for medical statistics. Bone Marrow Transplant 48:452– 458.
15. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C, Warshaw AL. (2006) Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24:2897– 2902.
16. Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, Thomsen KM et al. (2009) Predictive and prognostic value of CA 19-9 in resected pancre- atic adenocarcinoma. J Gastrointest Surg 13:2050– 2058.
17. Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C et al. (2013) CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 20: 2188– 2196.
18. Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB et al. (2013) Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J 54:643 –649.
19. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. (2013) FDG-PET in diag- nosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol 19:4808– 4817.
20. Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R et al. (2013) Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treat- ment response, and detection of recurrence. Pancreas 42:11 – 19.
21. Lall CG, Howard TJ, Skandarajah A, DeWitt JM, Aisen AM, Sandrasegaran K. (2007) New concepts in staging and treatment of locally advanced pancreatic head cancer. Am J Roentgenol 189: 1044– 1050.
22. Takemura N, Miki K, Kosuge T. (2016) New portal-superior mesenteric vein reconstructions using first jejunal vein flap in pancreaticoduode- nectomy. World J Surg 40:1462 –1466.
23. Fujii T, Nakao A, Yamada S, Suenaga M, Hattori M, Takami H et al. (2015) Vein resections >3 cm during pancreatectomy are associated with poor 1-year patency rates. Surgery 157:708– 715.
24. Tas F, Sen F, Odabas H, Kilic L, Keskin S, Yildiz I. (2013) Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 18:839 – 846.
25. Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM et al. (2014) Morbidity and mortality after pancreaticoduodenectomy in pa- tients with borderline resectable type C clinical classification. J Gastrointest Surg 18:146– 156.
26. Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ et al. (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 18:2318 –2328.
27. Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M et al. (2016) Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter. Medicine (Baltim) 95:e3582.
28. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL et al. (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Surg 109:416 –421.
29. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH et al. (2012) Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol (Northwood) 29: 3092– 3100.
30. Watanabe J, Otani S, Sakamoto T, Arai Y, Hanaki T, Amisaki M et al. (2016) Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer. Surg Today 46:1258– 1267.